Activity of novel antifungal compound APX001A against a large collection of Candida auris

Abstract

Background: APX001A is an antifungal agent that targets a novel pathway—glycosylphosphatidylinositol glycolipid biosynthesis. It has been shown to be effective against a variety of fungal species, including Candida spp., Aspergillus spp. and other filamentous fungi. Objectives: To determine the activity of APX001A against the emerging fungal pathogen Candida auris. Methods: APX001A was tested by broth microdilution against 100 geographically distinct isolates of C. auris. Results: APX001A showed activity against all isolates, including some that were resistant to one or more anti-fungals, with MIC50 and MIC90 of 0.002 and 0.008 mg/L, respectively. Conclusions: These findings suggest that APX001A shows encouraging activity against the emerging fungal pathogen C. auris.